<DOC>
	<DOCNO>NCT02679235</DOCNO>
	<brief_summary>BEAT7-001 randomise , open label , two parallel group study ( supplementation versus control ) . Using multi-modal brain imaging portfolio , study ass whether brain energy metabolism ( glucose ketone ) , structure functional connectivity change old people frontal glucose hypometabolism 28 day oral dose 1 g/kg/day triheptanoin .</brief_summary>
	<brief_title>Brain Energy Aging With Triheptanoin</brief_title>
	<detailed_description />
	<criteria>Men woman ≥65 year old ; Score ≥26/30 Montreal Cognitive Assessment ; ≥10 % low brain glucose uptake frontal cortex determine PET image . Score &lt; 26/30 Montreal Cognitive Assessment ; Medications likely affect primary cognitive outcome ; Medical psychiatric condition could interfere study participation ( Peterson et al . 2005 ) ; Fasting plasma glucose ≥7.0 mM ( avoid recruiting diabetic prediabetics , risk factor cognitive impairment old person ( Mortimer et al . 2010 ) also inhibit ketogenesis ( Fukao et al . 2004 ) ; Clinicallysignificant gastrointestinal disease/conditions ; Clinicallysignificant liver disease/dysfunction : ALT ≥37 UI/L , AST ≥36 UI/L , Total bilirubin ≥26 μmol/L ; Clinicallysignificant renal disease/dysfunction : creatinine ≥92 μmol/L , glomerular filtration rate &lt; 60 ml/min/1.73 m2 &gt; 90 ml/min/1.73 m2 ; Clinicallysignificant cardiac disease/conditions ; Clinicallysignificant abnormal coagulation laboratory result coagulation disorder screen ; Poorly control dyslipidemia ( total cholesterol ≥6.2 mmol/L triglyceride ≥2.20 mmol/L ) Hypertension : ≥140/90 mmHg ; Substance abuse ; Already MCT supplementation ; Visual hearing impairment impede comprehension ; NonFrench speaking ; Any condition life expectancy le 5 year ; Institutionalized intend move area within 1 year ; Participation intervention trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>